- Home
- PRKS vs IMVT Comparison
PRKS vs IMVT Comparison
Compare PRKS & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRKS
- IMVT
- Stock Information
- Founded
- PRKS 1959
- IMVT 2018
- Country
- PRKS United States
- IMVT United States
- Employees
- PRKS N/A
- IMVT N/A
- Industry
- PRKS Biotechnology: Electromedical & Electrotherapeutic Apparatus
- IMVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PRKS Health Care
- IMVT Health Care
- Exchange
- PRKS Nasdaq
- IMVT Nasdaq
- Market Cap
- PRKS 2.8B
- IMVT 2.7B
- IPO Year
- PRKS 2013
- IMVT N/A
- Fundamental
- Price
- PRKS $51.25
- IMVT $21.98
- Analyst Decision
- PRKS Buy
- IMVT Buy
- Analyst Count
- PRKS 10
- IMVT 9
- Target Price
- PRKS $56.40
- IMVT $27.71
- AVG Volume (30 Days)
- PRKS 684.0K
- IMVT 1.7M
- Earning Date
- PRKS 11-06-2025
- IMVT 11-10-2025
- Dividend Yield
- PRKS N/A
- IMVT N/A
- EPS Growth
- PRKS N/A
- IMVT N/A
- EPS
- PRKS 3.77
- IMVT N/A
- Revenue
- PRKS $1,707,446,000.00
- IMVT N/A
- Revenue This Year
- PRKS $0.91
- IMVT N/A
- Revenue Next Year
- PRKS $2.35
- IMVT N/A
- P/E Ratio
- PRKS $13.59
- IMVT N/A
- Revenue Growth
- PRKS N/A
- IMVT N/A
- 52 Week Low
- PRKS $37.68
- IMVT $12.72
- 52 Week High
- PRKS $60.83
- IMVT $32.10
- Technical
- Relative Strength Index (RSI)
- PRKS 46.88
- IMVT 78.23
- Support Level
- PRKS $49.69
- IMVT $18.51
- Resistance Level
- PRKS $52.03
- IMVT $19.60
- Average True Range (ATR)
- PRKS 1.77
- IMVT 1.04
- MACD
- PRKS -0.24
- IMVT 0.40
- Stochastic Oscillator
- PRKS 31.26
- IMVT 99.66
About PRKS United Parks & Resorts Inc. Common Stock
United Parks & Resorts Inc is an American theme park and entertainment company. Its core business is the operation of theme parks and entertainment facilities involving sea animals across the country under prominent brands such as SeaWorld, Busch Gardens, Aquatica, Discovery Cove, and Sesame Place. The company generates the majority of its revenue from selling admission tickets for its theme parks.
About IMVT Immunovant Inc.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.